Overview

Nanoparticle Albumin-Bound Rapamycin and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas

Status:
Recruiting

Trial end date:
2024-02-28

Target enrollment:

Participant gender:

Summary

This phase I/II trial studies the side effects and best dose of nanoparticle albumin-bound rapamycin and how well it works when given together with pazopanib hydrochloride in treating participants with nonadipocytic soft tissue sarcomas that has spread to other places in the body (advanced). Nanoparticle albumin-bound rapamycin and pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University of Washington

Collaborator:

Aadi, LLC

Treatments:

Everolimus
Sirolimus